230 related articles for article (PubMed ID: 33876230)
1. Hepatitis C Virus Direct-Acting Antiviral Treatment Adherence Patterns and Sustained Viral Response Among People Who Inject Drugs Treated in Opioid Agonist Therapy Programs.
Heo M; Pericot-Valverde I; Rennert L; Akiyama MJ; Norton BL; Gormley M; Agyemang L; Arnsten JH; Litwin AH
Clin Infect Dis; 2021 Dec; 73(11):2093-2100. PubMed ID: 33876230
[TBL] [Abstract][Full Text] [Related]
2. Optimal hepatitis C treatment adherence patterns and sustained virologic response among people who inject drugs: The HERO study.
Heo M; Norton BL; Pericot-Valverde I; Mehta SH; Tsui JI; Taylor LE; Lum PJ; Feinberg J; Kim AY; Arnsten JH; Sprecht-Walsh S; Page K; Murray-Krezan C; Anderson J; Litwin AH;
J Hepatol; 2024 May; 80(5):702-713. PubMed ID: 38242324
[TBL] [Abstract][Full Text] [Related]
3. Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial.
Akiyama MJ; Norton BL; Arnsten JH; Agyemang L; Heo M; Litwin AH
Ann Intern Med; 2019 May; 170(9):594-603. PubMed ID: 30959528
[TBL] [Abstract][Full Text] [Related]
4. Overreporting of adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs in the HERO study.
Lopes SS; Pericot-Valverde I; Lum PJ; Taylor LE; Mehta SH; Tsui JI; Feinberg J; Kim AY; Norton BL; Page K; Murray-Krezan C; Anderson J; Karasz A; Arnsten J; Moschella P; Heo M; Litwin AH
BMC Infect Dis; 2024 Feb; 24(1):251. PubMed ID: 38395747
[TBL] [Abstract][Full Text] [Related]
5. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.
Macías J; Morano LE; Téllez F; Granados R; Rivero-Juárez A; Palacios R; Ríos M; Merino D; Pérez-Pérez M; Collado A; Figueruela B; Morano A; Freyre-Carrillo C; Martín JM; Rivero A; García F; Pineda JA;
J Hepatol; 2019 Jul; 71(1):45-51. PubMed ID: 30853642
[TBL] [Abstract][Full Text] [Related]
6. Direct-acting antiviral therapy for hepatitis C infection among people receiving opioid agonist treatment or heroin assisted treatment.
Scherz N; Bruggmann P; Brunner N
Int J Drug Policy; 2018 Dec; 62():74-77. PubMed ID: 30368101
[TBL] [Abstract][Full Text] [Related]
7. Direct acting antiviral-based treatment of hepatitis C virus infection among people who inject drugs in Georgia: A prospective cohort study.
Bouscaillou J; Kikvidze T; Butsashvili M; Labartkava K; Inaridze I; Etienne A; Le Pluart D; Kamkamidze G; Gamezardashvili A; Kharshiladze D; Avril E; Luhmann N
Int J Drug Policy; 2018 Dec; 62():104-111. PubMed ID: 30384026
[TBL] [Abstract][Full Text] [Related]
8. Low Hepatitis C Reinfection Following Direct-acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy.
Akiyama MJ; Lipsey D; Heo M; Agyemang L; Norton BL; Hidalgo J; Lora K; Litwin AH
Clin Infect Dis; 2020 Jun; 70(12):2695-2702. PubMed ID: 31346609
[TBL] [Abstract][Full Text] [Related]
9. Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy.
Cunningham EB; Hajarizadeh B; Amin J; Litwin AH; Gane E; Cooper C; Lacombe K; Hellard M; Read P; Powis J; Dalgard O; Bruneau J; Matthews GV; Feld JJ; Dillon JF; Shaw D; Bruggmann P; Conway B; Fraser C; Marks P; Dore GJ; Grebely J;
Clin Infect Dis; 2020 Oct; 71(7):e115-e124. PubMed ID: 31677262
[TBL] [Abstract][Full Text] [Related]
10. Rates of perfect self-reported adherence to direct-acting antiviral therapy and its correlates among people who inject drugs on medications for opioid use disorder: The PREVAIL study.
Pericot-Valverde I; Rennert L; Heo M; Akiyama MJ; Norton BL; Agyemang L; Lumsden B; Litwin AH
J Viral Hepat; 2021 Mar; 28(3):548-557. PubMed ID: 33249689
[TBL] [Abstract][Full Text] [Related]
11. Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial.
Litwin AH; Lum PJ; Taylor LE; Mehta SH; Tsui JI; Feinberg J; Kim AY; Norton BL; Heo M; Arnsten J; Meissner P; Karasz A; Mckee MD; Ward JW; Johnson N; Pericot-Valverde I; Agyemang L; Stein ES; Thomas A; Borsuk C; Blalock KL; Wilkinson S; Wagner K; Roche J; Murray-Krezan C; Anderson J; Jacobsohn V; Luetkemeyer AF; Falade-Nwulia O; Page K;
Lancet Gastroenterol Hepatol; 2022 Dec; 7(12):1112-1127. PubMed ID: 36370741
[TBL] [Abstract][Full Text] [Related]
12. Changes in Health-related Quality of Life for Hepatitis C Virus-Infected People Who Inject Drugs While on Opioid Agonist Treatment Following Sustained Virologic Response.
Gormley MA; Akiyama MJ; Rennert L; Howard KA; Norton BL; Pericot-Valverde I; Muench S; Heo M; Litwin AH
Clin Infect Dis; 2022 May; 74(9):1586-1593. PubMed ID: 34331539
[TBL] [Abstract][Full Text] [Related]
13. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data.
Palmateer NE; McAuley A; Dillon JF; McDonald S; Yeung A; Smith S; Barclay S; Hayes P; Shepherd SJ; Gunson RN; Goldberg DJ; Hickman M; Hutchinson SJ
Addiction; 2021 Oct; 116(10):2893-2907. PubMed ID: 33651446
[TBL] [Abstract][Full Text] [Related]
14. Predictors of hepatitis C cure among people who inject drugs treated with directly observed therapy supported by peer case managers in Kenya.
Akiyama MJ; Riback LR; Nyakowa M; Musyoki H; Lizcano JA; Muller A; Zhang C; Walker JG; Stone J; Vickerman P; Cherutich P; Kurth AE
Int J Drug Policy; 2023 Mar; 113():103959. PubMed ID: 36758335
[TBL] [Abstract][Full Text] [Related]
15. Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?
Panagiotoglou D; Krebs E; Min JE; Olding M; Ahamad K; Ti L; Montaner JSG; Nosyk B
Int J Drug Policy; 2017 Sep; 47():169-176. PubMed ID: 28578865
[TBL] [Abstract][Full Text] [Related]
16. HIV And HCV adherence and treatment outcomes among people who inject drugs receiving opioid agonist therapy.
J Minhas H; Akiyama MJ; Norton BL; Heo M; Arnsten JH; Litwin AH
AIDS Care; 2022 Oct; 34(10):1229-1233. PubMed ID: 34533062
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus treatment in people who inject drugs (PWID) in Bangladesh.
Rahman M; Janjua NZ; Shafiq TKI; Chowdhury EI; Sarker MS; Khan SI; Reza M; Faruque MO; Kabir A; Anis AH; Azim T
Int J Drug Policy; 2019 Dec; 74():69-75. PubMed ID: 31542689
[TBL] [Abstract][Full Text] [Related]
18. Factors and HCV treatment outcomes associated with smoking among people who inject drugs on opioid agonist treatment: secondary analysis of the PREVAIL randomized clinical trial.
Pericot-Valverde I; Heo M; Akiyama MJ; Norton BL; Agyemang L; Niu J; Litwin AH
BMC Infect Dis; 2020 Dec; 20(1):928. PubMed ID: 33276738
[TBL] [Abstract][Full Text] [Related]
19. Self-reported and measured adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs: The HERO study.
Lopes SS; Pericot-Valverde I; Arnsten J; Lum PJ; Taylor LE; Mehta SH; Tsui JI; Feinberg J; Kim AY; Norton BL; Page K; Murray-Krezan C; Anderson J; Moschella P; Heo M; Litwin AH
Int J Drug Policy; 2024 Jan; 123():104288. PubMed ID: 38103458
[TBL] [Abstract][Full Text] [Related]
20. Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV).
Fadnes LT; Aas CF; Vold JH; Leiva RA; Ohldieck C; Chalabianloo F; Skurtveit S; Lygren OJ; Dalgård O; Vickerman P; Midgard H; Løberg EM; Johansson KA;
PLoS Med; 2021 Jun; 18(6):e1003653. PubMed ID: 34061883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]